The depletion of PRKN also enhanced pancreatic tumorigenesis in KRAS-driven engineered mouse models based on its role in mediating the degradation of mitochondrial iron importers (Kang et al., 2019), implying that PRKN can be a potential target for pancreatic cancer therapy. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.